Holen Sie sich die Stockscreener-App
3.67
0.41%
-0.05
Liminatus Pharma Inc Aktie (LIMN) Neueste Nachrichten
Enterprise value to EBITDA forward of Liminatus Pharma, Inc. – NASDAQ:LIMNW - TradingView
Price to sales forward of Liminatus Pharma, Inc. – BOATS:LIMNW - TradingView
Liminatus Pharma selects Synex to advance CAR-T trial - Clinical Trials Arena
Liminatus engages Synex for IBC101 CAR-T clinical development - Investing.com
Liminatus Pharma Engages Synex Consulting to Support Clinical Development of IBC101 CAR-T Therapy in South Korea - quiverquant.com
Liminatus engages Synex for IBC101 CAR-T clinical development By Investing.com - Investing.com UK
Korea’s Ministry of Food and Drug Safety authorizes Liminatus study - Stock Titan
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy - finance.yahoo.com
Nasdaq Orders Immediate Suspension of Flash Sports & Media Stock - Minichart
Press Releases about Liminatus Pharma, Inc.Class A Common Stock (Nasdaq:LIMN) - FinancialContent
17,272,739 Common Stock of Liminatus Pharma, Inc. are subject to a Lock-Up Agreement Ending on 19-AUG-2026. - marketscreener.com
Liminatus Pharma to implement 1-for-50 reverse stock split - Investing.com
Liminatus Pharma Enacts Reverse Split to Maintain Listing - TipRanks
Liminatus Pharma announces 1-for-50 reverse stock split - TipRanks
Liminatus Pharma to implement 1-for-50 reverse stock split By Investing.com - Investing.com India
Liminatus Pharma Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock - The Manila Times
Liminatus Pharma, Inc. Announces Reverse Stock Split of Its Common Stock - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Liminatus Pharma (LIMN) Stock Analysis Report | Financials & Insights - Benzinga France
Liminatus Pharma Warrants (LIMNW) Tumble 13.79% to $0.05 as Key Level Comes Into FocusScalping Stock Signals - vinanet.vn
Liminatus Pharma (LIMN) Slides 6.6% to $0.14, Testing Critical $0.13 SupportLow Vol ETF - vinanet.vn
Liminatus Pharma, Inc. Q2 2026: Net income $(1.41)M, EPS $(0.03) — 10-Q Summary - TradingView
Liminatus Pharma (LIMN) logs $2.5M loss and fights Nasdaq listing threats - Stock Titan
Liminatus Pharma (LIMN) Stock Jumps Over 50% on a Listing Update - TipRanks
These stocks are the most active in today's session - ChartMill
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Liminatus Pharma moves to Nasdaq Capital Market By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Liminatus Pharma moves to Nasdaq Capital Market - Investing.com
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement - The Manila Times
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Bid Price Compliance - Quiver Quantitative
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance ... - Herald and News
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance With Minimum Bid Price Requirement - Moomoo
$Liminatus Pharma (LIMN.US)$ - moomoo.com
Liminatus Pharma Warrants (LIMNW) Jump 34% to $0.07 as Traders Eye Key Inflection PointFear Greed Extreme - vinanet.vn
Liminatus Pharma (LIMN) Edges Higher as Micro-Cap Biotech Holds Key $0.10 Support LevelTriple Bottom - dars.gov.et
Liminatus Pharma Shareholders Approve Reverse Stock Split Plan - The Globe and Mail
Liminatus Pharma Warrants (LIMNW) Remain Flat at $0.06 as Key Levels ConvergePut Dominated - dars.gov.et
Liminatus Pharma, Inc. Primary Exchange Listing has Changed to Nasdaq Capital Market from Nasdaq Global Market - marketscreener.com
Liminatus Pharma, Inc. Revenue Breakdown – NASDAQ:LIMN - TradingView
Liminatus Pharma Reports Improved Nasdaq Listing Compliance Status - TipRanks
Liminatus Pharma (NASDAQ: LIMN) cites $2.5M equity in Nasdaq compliance review - Stock Titan
LIMN|Liminatus Pharma Ord Shs Class A|Price:4.410|Chg%:-0.200 - TradingKey
LIMN|Liminatus Pharma Ord Shs Class A|Price:0.119|Chg%:+0.002 - TradingKey
Liminatus Pharma, Inc. Revenue Breakdown – NASDAQ:LIMNW - TradingView
Liminatus Pharma Faces Nasdaq Delisting Risk, Plans Reverse Split - The Globe and Mail
Liminatus Pharma, Inc. Revenue Breakdown – BOATS:LIMN - TradingView
Liminatus Pharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Liminatus Pharma, Inc. Class A Common Stock (NASDAQ: LIMN) Stock Price, News & Analysis - Kalkine
Samda Biolab discloses 5.1% Liminatus Pharma (LIMN) ownership position - Stock Titan
Frontier tech research, news & data - MLQ.ai
Liminatus Pharma Warrants (LIMNW) Edge Higher: A Closer Look at the $0.06 LevelHigh Yield Stocks - vinanet.vn
Enterprise value to EBITDA forward of Liminatus Pharma, Inc. – BOATS:LIMNW - TradingView
Liminatus Pharma (LIMN) Plunges 16.72% as Key Support Nears $0.11PCR Mean Reversion - vinanet.vn
Price to earnings forward of Liminatus Pharma, Inc. – BOATS:LIMNW - TradingView
Enterprise value to EBIT forward of Liminatus Pharma, Inc. – BOATS:LIMNW - TradingView
Liminatus Pharma (LIMN) - Moomoo
Liminatus Pharma Warrants Plunge 36%: Key Levels and Outlook for LIMNWIV Contraction - dars.gov.et
Curious about the most active stocks on Thursday? - ChartMill
Liminatus Pharma (LIMN) Stock Is Trending Overnight — Here’s Why it Spiked Over 30% in After-Hours Session - sahmcapital.com
Form 13D/A Liminatus Pharma For: 14 July By Investing.com - Investing.com Nigeria
Form 4 Liminatus Pharma Inc For: 14 July By Investing.com - Investing.com Nigeria
0.61%
3.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):